Metropolitan Life Insurance Company (MetLife)’s Fulcrum Therapeutics FULC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,849	Closed	-$8.12K	–	2480
2023 Q1	$8.12K	Buy	2,849 +771	+37%	+$6.91K	﹤0.01%	2224
2022 Q4	$15.1K	Hold	2,078	–	–	﹤0.01%	2129
2022 Q3	$16.8K	Buy	+2,078	New	+$14.9K	﹤0.01%	2105
2022 Q2	–	Sell	-1,783	Closed	-$42.2K	–	2393
2022 Q1	$42.2K	Sell	1,783 -5,446	-75%	-$77.1K	﹤0.01%	1690
2021 Q4	$128K	Hold	7,229	–	–	﹤0.01%	2332
2021 Q3	$204K	Buy	+7,229	New	+$137K	﹤0.01%	2052
2020 Q3	–	Sell	-4,328	Closed	-$79.2K	–	2576
2020 Q2	$79.2K	Buy	4,328 +3,313	+326%	+$52.2K	﹤0.01%	2384
2020 Q1	$12.1K	Buy	+1,015	New	+$16.2K	﹤0.01%	2481

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FULC Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 2,849 shares — an estimated $8.12K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FULC in Q1 2020 and held it in 8 quarters. The position peaked at $204K in Q3 2021. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,849 Fulcrum Therapeutics shares in Q2 2023, an estimated $8.12K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Fulcrum Therapeutics in Q1 2020 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Fulcrum Therapeutics position peaked at $204K in Q3 2021.
88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.